Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance, strategic product development, and a solid market strategy, particularly with the KOMZIFTI product showing strong momentum. The Q&A section further highlights the positive reception of KOMZIFTI, its combination use, and strong patient start metrics, reinforcing the positive outlook. The strategic plan and market opportunity also suggest a favorable long-term growth trajectory. Despite some uncertainty in management's responses, the overall sentiment remains positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Net Product Revenue from KOMZIFTI Sales $5.8 million compared to none in the first quarter of 2025. This increase is due to the first full quarter of the commercial launch of KOMZIFTI.
Collaboration Revenue from Kyowa Kirin Partnership $12.5 million compared to $14.1 million for the same period in 2025. The decrease is attributed to changes in performance obligations under the collaboration agreement.
Research and Development Expenses $65.3 million compared to $56 million for the first quarter of 2025. The increase was driven by ziftomenib combination trials, including the start of enrollment in KOMET-017 trials in the second half of 2025.
Selling, General and Administrative Expenses $31.6 million compared to $22.8 million for the first quarter of 2025. This increase was driven by the commercial launch of KOMZIFTI.
Net Loss $73.3 million compared to $57.4 million for the first quarter of 2025. This includes noncash share-based compensation expense of $8.4 million compared to $7.8 million for the same period in 2025.
Cash, Cash Equivalents, and Short-term Investments $580.8 million as of March 31, 2026, compared to $667.2 million as of December 31, 2025. The decrease reflects operational expenses and investments in ongoing programs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KOMZIFTI launch: Generated $5.8 million in net product revenue in the first full quarter of launch, exceeding expectations. Demonstrated broad uptake, repeat prescriptions, and increasing payer preference. Positioned as a leader in treating relapsed or refractory NPM1 mutant AML.
Ziftomenib combinations: Multiple data readouts expected in 2026 to support its use as a backbone therapy in AML treatment. Includes combinations with 7+3, venetoclax/azacitidine, and gilteritinib.
Darlifarnib progress: Demonstrated potential to overcome resistance to targeted therapies, with additional combination data expected in 2026, including KRAS G12C mutated cancers.
Market opportunity for KOMZIFTI: Targeting a $350 million to $400 million market for relapsed or refractory NPM1 mutant AML. Achieved 93% coverage parity or better with favorable formulary positioning.
Operational execution: Streamlined Phase III trial enrollment with the KOMET-017 program ahead of schedule. Rapid prescription-to-patient receipt time of approximately 3 days.
Financial performance: Net product revenue of $5.8 million from KOMZIFTI sales. Increased R&D and SG&A expenses due to commercial launch and trials. Cash reserves of $580.8 million as of March 31, 2026.
Strategic focus on AML: Positioning ziftomenib as a combinable backbone therapy across AML treatment continuum. Expanding into frontline and relapsed settings with innovative trial designs.
Broader pipeline development: Exploring menin inhibition in solid tumors and advancing darlifarnib combinations in KRAS G12C mutated cancers and other indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: Physicians switching patients from other menin inhibitors to KOMZIFTI indicates competitive pressures within the menin inhibitor class. The company must continue to differentiate its product to maintain and grow its market share.
Regulatory and Access Challenges: Although KOMZIFTI has achieved broad coverage, maintaining favorable formulary positioning and payer preferences will require ongoing efforts to demonstrate value and manage costs.
Operational Execution: The company’s ability to maintain rapid prescription-to-patient timelines and strong engagement across academic and community settings is critical. Any disruptions in these areas could impact product adoption and revenue growth.
Financial Sustainability: The company reported a net loss of $73.3 million for Q1 2026, an increase from the previous year. This highlights the need for careful financial management to sustain operations and fund ongoing clinical trials.
Clinical Development Risks: The success of ongoing and future clinical trials, including the KOMET-017 Phase III program, is crucial for the company’s strategy. Any delays or negative outcomes could significantly impact its growth prospects.
Pipeline Expansion: Efforts to expand the use of ziftomenib and develop darlifarnib in new indications carry inherent risks, including the potential for clinical or regulatory setbacks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
KOMZIFTI Expansion: Kura Oncology plans to expand ziftomenib (KOMZIFTI) across the AML treatment continuum and establish it as a backbone therapy in combination. Multiple data readouts are expected in 2026, including updated data from the 7+3 combination in newly diagnosed AML, publication of venetoclax/azacitidine combination data, and initial data from the gilteritinib combination in relapsed and refractory AML patients with NPM1 and FLT3 co-mutations.
Phase III Program Progress: The KOMET-017 Phase III program is progressing ahead of plan with strong enrollment across leading global sites. The innovative one-stop shop design is accelerating execution without compromising rigor.
Broader Pipeline Development: Beyond AML, Kura is advancing its broader pipeline, including darlifarnib, which has shown potential to overcome resistance to targeted therapies. Additional combination data, including in KRAS G12C mutated cancers, is expected in 2026.
Ziftomenib Data Updates: In 2026, Kura expects to present updated data from ziftomenib in combination with 7+3 in newly diagnosed AML, publish data on venetoclax/azacitidine combinations, and provide preliminary data on gilteritinib combinations in relapsed or refractory AML patients.
Darlifarnib Development: Darlifarnib is progressing with enrollment in the Phase Ib portion of its trial in combination with cabozantinib. Preliminary data on darlifarnib plus adagrasib in KRAS G12C mutated solid tumors will be presented at ASCO 2026.
Financial Guidance: Kura expects collaboration revenue of $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028. Current cash and anticipated payments are expected to fund the ziftomenib AML program through the first top-line Phase III results from KOMET-017 anticipated in 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us some color on how we should think about the duration of treatment with KOMZIFTI early on, given that it sounds like you have patients on monotherapy as well as some that might be receiving combination?
A:It is difficult to provide too much detail on the duration of treatment with only one full quarter of data. The expectation is around 6 months of treatment. The focus is currently on the number of new patient starts, with 85 new patient starts being a positive indicator. More data over several quarters is needed to better understand the duration.
Q:What have you learned from KOMET-007 about the dose profile in the front line, especially over longer-term use? Is there some response deepening happening?
A:The staggered start approach allows patients to remain on treatment without interruptions or dose reductions due to adverse events. This approach helps deepen responses over time and enables continuation into post-transplant or post-consolidation treatments. The data from KOMET-007 reinforces the design of KOMET-017, which is expected to yield great outcomes for frontline patients.
Q:Can you provide more color on what you're seeing in terms of initial combination use and instances of switching from other menin inhibitors? How common is combination use in switching?
A:Approximately 40% of patients are using KOMZIFTI in combination, either with ven/aza or gilteritinib for FLT3 co-mutated cases. Switching from other menin inhibitors has been observed but is expected to be less significant than combination use. The switching demonstrates the strength of KOMZIFTI's profile and supports its strong early momentum.
Q:What is the primary reason patients have been switching from other menin inhibitors?
A:Physicians are switching patients to KOMZIFTI based on its profile, which may include efficacy, safety, and simplicity of use. However, detailed reasons for each switch are not available. The focus remains on new patient starts, which indicate strong momentum for KOMZIFTI.
Q:Can you provide additional color on new patient starts, gross-to-net dynamics, and the total number of accounts being targeted?
A:New patient starts are strong, with 40% of new patient starts in the first quarter. Scripts are typically for 1 month, and gross-to-net dynamics are within the normal range of 20%-30%. There are currently 60 activated accounts, with plans to expand further to become the market leader.
Q:Can you give us color on how combination use looks in academic and community settings, and how it might evolve with more data?
A:Combination use is not actively promoted but is based on data. The publication of ven/aza data and FLT3 combo data in the second half of the year is expected to drive momentum. KOMZIFTI's unique profile, including its ability to combine with FLT3 inhibitors, positions it strongly in the market.
Q:What measures do you think investigators and physicians will evaluate most prominently when considering menin inhibitors in the frontline?
A:Physicians will evaluate a combination of factors, including survival, durability of response, progression to transplant, and MRD negativity. High response rates (in the high 90s) and MRD negativity (in the 80s) are strong indicators of deep responses and potential survival benefits.
Q:Can you comment on the cadence of the 40% new patient starts and whether it reflects the exit NBRx share for NPM1?
A:The 40% new patient starts in the first full quarter is a strong indicator of momentum. While there is variability week-to-week and month-to-month, the focus is on becoming the market leader in relapsed/refractory NPM1. The team is optimistic about building on this early success.
Q:How much of the $5.8 million revenue is inventory stocking, and how might combination use extend the duration of therapy?
A:There is no meaningful inventory stocking in the $5.8 million revenue. Combination use is expected to extend the duration of therapy beyond 6 months, but more data over the next few quarters is needed to confirm this.
Q:Will there be any monotherapy data at ASCO, or just combination data for darlifarnib with adagrasib?
A:Monotherapy data was previously presented last year. At ASCO, the focus will be on combination data for darlifarnib with adagrasib across multiple tumor types, including non-small cell lung, PDAC, and colorectal cancer.
Q:Can you provide more details on the KOMET-017 trial progress and whether it changes guidance for future readouts?
A:The KOMET-017 trial is progressing ahead of schedule, with strong participation across the U.S., Europe, and Asia. Guidance for initial top-line results from the intensive chemotherapy combo remains set for 2028, with no changes at this time.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the primary reasons for patients switching from other menin inhibitors, citing a lack of detailed data on individual cases. Additionally, they were vague about the duration of therapy in combination use, stating that more data is needed over the next few quarters to provide clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FLT
KOMZIFTI
Kyowa Kirin
NPM
Oncology
Phase III
Troy
access
approach
backbone
center
collaboration
combination AML
darlifarnib
design
efficacy safety
enrollment
frontline
inhibitor class
launch
menin
patient
payer
physician
prescription
product profile
recognition
role
setting
therapy
treatment decision
use
venetoclax azacitidine
world
ziftomenib combination
KURA Transcript
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call summary reveals strong financial performance, strategic product development, and a solid market strategy, particularly with the KOMZIFTI product showing strong momentum. The Q&A section further highlights the positive reception of KOMZIFTI, its combination use, and strong patient start metrics, reinforcing the positive outlook. The strategic plan and market opportunity also suggest a favorable long-term growth trajectory. Despite some uncertainty in management's responses, the overall sentiment remains positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
CareRx Corporation (CRRX:CA) Q4 2025 Earnings Call Transcript
Positive3-5
The company's financial performance shows improvement, with increased revenue, EBITDA, and net income. There is a clear strategy for growth with new bed onboarding and expansion plans. The Q&A reveals active pursuit of growth opportunities, though some responses lack specificity. Overall, the strong financial results and strategic initiatives suggest a positive outlook, likely leading to a stock price increase of 2% to 8%.
KURA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
